Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002521501 | SCV003442528 | uncertain significance | Facioscapulohumeral muscular dystrophy 2 | 2022-06-12 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 345 of the SMCHD1 protein (p.Gln345Arg). This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change does not substantially affect SMCHD1 function (PMID: 31312724). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 375760). This missense change has been observed in individual(s) with autosomal dominant Bosma arhinia microphthalmia syndrome (PMID: 28067909). It has also been observed to segregate with disease in related individuals. |
MGH Harvard Center for Reproductive Medicine, |
RCV000417316 | SCV000328608 | pathogenic | Arrhinia with choanal atresia and microphthalmia syndrome | no assertion criteria provided | research | ||
MGH Harvard Center for Reproductive Medicine, |
RCV000497013 | SCV000328609 | pathogenic | Anosmia | no assertion criteria provided | research | ||
OMIM | RCV000417316 | SCV000503075 | pathogenic | Arrhinia with choanal atresia and microphthalmia syndrome | 2017-02-27 | no assertion criteria provided | literature only |